Genor Biopharma Holdings (FRA:67N0) Short Interest


FRA:67N0 Genor Biopharma Holdings Ltd FRA:67N0
22 GF Score
Price €0.34
! 1 Warning Sign
View Full Analysis

What is Genor Biopharma Holdings Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:67N0 vs VRTX, REGN, ALNY: Short Interest Comparison

For the Biotechnology subindustry, Genor Biopharma Holdings's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genor Biopharma Holdings Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genor Biopharma Holdings's Short Interest distribution charts can be found below:

* The bar in red indicates where Genor Biopharma Holdings's Short Interest falls into.


FRA:67N0
22GF Score
Genor Biopharma Holdings Ltd FRA:67N0
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genor Biopharma Holdings Business Description

Address 690 Bibo Road, Room 501-02, Building 6, Pudong New District, Shanghai, CHN, 201203
Genor Biopharma Holdings Ltd is a commercial-ready biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. The company is focused on therapeutic areas with substantial unmet medical needs in oncology, autoimmune, and other chronic diseases. Its key drug candidates includes GB491 (lerociclib), a differentiated oral CDK4/6 inhibitor; GB221, a novel HER2 mAb drug candidate; geptanolimab (GB226), GB492, a STING agonist expected to exert synergistic effects in combination with GB226; GB242, an infliximab (Remicade) biosimilar; and GB223, a RANKL, and others.
22GF Score

Get the complete analysis for FRA:67N0

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.34
Price